CLINICAL TRIALS PROFILE FOR BUMETANIDE
✉ Email this page to a colleague
All Clinical Trials for Bumetanide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00372762 ↗ | Bumetanide Versus Furosemide in Heart Failure | Withdrawn | University of Western Ontario, Canada | Phase 3 | 2011-01-01 | Patients with NYHA FC II-III heart failure will be randomized in a cross-over fashion to 8 weeks of bumetanide versus furosemide therapy (equipotent dose), to test whether bumetanide therapy has a superior effect on insulin resistance compared to furosemide. Patients will be subject to a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal model (MINMOD) analysis to assess insulin resistance and to a 6-minute walk test (6MWT) to assess functional capacity; patient recruitment and retention success, as well as medication adherence, will also be assessed. |
| NCT00372762 ↗ | Bumetanide Versus Furosemide in Heart Failure | Withdrawn | Lawson Health Research Institute | Phase 3 | 2011-01-01 | Patients with NYHA FC II-III heart failure will be randomized in a cross-over fashion to 8 weeks of bumetanide versus furosemide therapy (equipotent dose), to test whether bumetanide therapy has a superior effect on insulin resistance compared to furosemide. Patients will be subject to a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal model (MINMOD) analysis to assess insulin resistance and to a 6-minute walk test (6MWT) to assess functional capacity; patient recruitment and retention success, as well as medication adherence, will also be assessed. |
| NCT00830531 ↗ | Pilot Study of Bumetanide for Newborn Seizures | Completed | Charles H. Hood Foundation | Phase 1 | 2010-01-01 | The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone. |
| NCT00830531 ↗ | Pilot Study of Bumetanide for Newborn Seizures | Completed | Citizens United for Research in Epilepsy | Phase 1 | 2010-01-01 | The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone. |
| NCT00830531 ↗ | Pilot Study of Bumetanide for Newborn Seizures | Completed | Harvard Catalyst- Harvard Clinical and Translational Science Center | Phase 1 | 2010-01-01 | The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone. |
| NCT00830531 ↗ | Pilot Study of Bumetanide for Newborn Seizures | Completed | Mooney Family Initiative for Translational Studies in Rare Diseases, Boston Children's Hospital | Phase 1 | 2010-01-01 | The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone. |
| NCT00830531 ↗ | Pilot Study of Bumetanide for Newborn Seizures | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 | 2010-01-01 | The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Bumetanide
Condition Name
Clinical Trial Locations for Bumetanide
Trials by Country
Clinical Trial Progress for Bumetanide
Clinical Trial Phase
Clinical Trial Sponsors for Bumetanide
Sponsor Name
